Immune checkpoint inhibitors (ICIs) have permanently changed the landscape of cancer therapy. However, up to half of patients who receive ICIs experience immune-related adverse events (irAEs), and some portion (1-2%, perhaps more) experience cardiotoxicity, such as myocarditis or other cardiovascular events. Recognizing ICI-related cardiotoxicity and initiating prompt treatment is critical. Whether to restart these patients on ICIs is controversial. ICI-related cardiotoxicity is rare, but clear guidelines to screen and treat CV toxicity are lacking, and clinicians need education on cardiotoxic effects of ICI therapy and guidance on rechallenging with ICI therapy.
This initiative seeks to fill those knowledge gaps among cardiologists and clinicians caring for patients with cancer who receive ICI therapy. Clinicians will receive education on the available clinical evidence to make informed decisions regarding resumption of therapy.
At the end of this CME/CE activity, participants should be able to:
Supported by educational grant from Bristol Myers Squibb.
Cardiologists, oncologists, PCPs, PAs, NPs, nurses, and pharmacists.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Reynolds reports the following financial relationships: Research Support: Project Data Sphere (a non-profit company). Stock Shareholder (ownership interest): Biogen. Other Financial or Material Support: (ownership interest): Teledoc Health, Inc.
Dr. Neilan reports the following financial relationships: Consultant: AbbVie Inc.; Bristol Myers Squibb; CRO Oncology; C4-Therapeutics, Inc.; Genentech, Inc.; Roche; and Sanofi. Grants: AstraZeneca and Bristol Myers Squibb
The following peer reviewer and CME Outfitters staff have no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at 877.CME.PROS (877.263.7767).